1. Corrigendum to "Efficacy + safety of palbociclib (P) in patients (pts) ≤50 y with hormone receptor‒positive (HR+)/human epidermal growth factor receptor 2‒negative (HER2–) advanced breast cancer (ABC): Subgroup analysis of 2 randomized phase 3 studies" [Breast 41S1 (2018) S11–12]. (February 2020) Authors: Cristofanilli, Massimo; Harbeck, Nadia; Rugo, Hope S.; Castrellon, Aurelio; Joy, Anil Abraham; Verma, Sunil; Im, Seock-Ah; Iyer, Shrividya; Puyana Theall, Kathy; Gauthier, Eric; Huang, Xin; Bartlett, Cynthia Huang; Loibl, Sibylle; Finn, Richard S. Journal: Breast Issue: Volume 49(2020) Page Start: 131 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Efficacy + safety of palbociclib (P) in patients (pts) ≤50 y with hormone receptor‒positive (HR+)/human epidermal growth factor receptor 2‒negative (HER2–) advanced breast cancer (ABC): subgroup analysis of 2 randomized phase 3 studies. (October 2018) Authors: Cristofanilli, Massimo; Harbeck, Nadia; Rugo, Hope; Castrellon, Aurelio; Joy, Anyl A.; Verma, Sunil; Im, Seock-Ah; Iyer, Shrividya; Puyana, Kathy; Gauthier, Eric; Huang, Xin; Bartlett, Cynthia Huang; Loibl, Sibylle; Finn, Richard S. Journal: Breast Issue: Volume 41(2018)Supplement 1 Page Start: S11 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Efficacy and safety of palbociclib plus endocrine therapy in North American women with hormone receptor‐positive/human epidermal growth factor receptor 2‐negative metastatic breast cancer. Issue 3 (25th August 2019) Authors: Gelmon, Karen A.; Cristofanilli, Massimo; Rugo, Hope S.; DeMichele, Angela M.; Joy, Anil A.; Castrellon, Aurelio; Sleckman, Bethany; Mori, Ave; Theall, Kathy Puyana; Lu, Dongrui R.; Huang, Xin; Bananis, Eustratios; Finn, Richard S.; Slamon, Dennis J. Journal: Breast journal Issue: Volume 26:Issue 3(2020) Page Start: 368 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Phase Ib/II single-arm trial evaluating the combination of everolimus, lapatinib and capecitabine for the treatment of HER2-positive breast cancer with brain metastases (TRIO-US B-09). (November 2018) Authors: Hurvitz, Sara; Singh, Rashi; Adams, Brad; Taguchi, Julie A.; Chan, David; Dichmann, Robert A.; Castrellon, Aurelio; Hu, Eddie; Berkowitz, Jonathan; Mani, Aruna; DiCarlo, Brian; Callahan, Rena; Smalberg, Ira; Wang, Xiaoyan; Meglar, Ivana; Martinez, Diego; Hobbs, Evthokia; Slamon, Dennis J. Journal: Therapeutic advances in medical oncology Issue: Volume 10(2018) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗